Orthobiologics Explained: PRP, PRF, BMAC and Donor Products

What this means

Orthobiologics is an umbrella, not a single injection. Clinics use the word for products meant to influence musculoskeletal pain, healing, or function. The usual menu is autologous blood preparations (PRP and PRF), autologous marrow concentrate (BMAC), adipose-derived preparations, and donor birth-tissue products such as amniotic suspension or umbilical-cord material. Composition, dose, evidence, and FDA status do not transfer from one vial to another.

Autologous means the starting material is yours. PRP is anticoagulated blood spun to raise platelet concentration. PRF is often prepared without anticoagulant so a fibrin matrix forms. BMAC is marrow aspirated from bone, usually the pelvis, then concentrated. These products still involve needles, processing kits, and injection into a joint, tendon, or disc. “From your own body” is a source statement, not a safety certificate.

Donor products are someone else’s tissue. FDA regulates many of these as human cells, tissues, and cellular and tissue-based products (HCT/Ps). Screening and processing rules exist because infection and misidentification are possible. Marketing a vial as live stem cells for arthritis or neuropathy does not establish what is in it or that the use is approved.

This page is for adults offered a regenerative injection for joint or tendon pain. It is not a protocol, and it is not a reason to skip fracture care, infection workup, or cancer evaluation of a destructive bone lesion.

What the evidence shows

Evidence is mixed and product-specific. PRP has the largest orthopedic literature. Some trials and reviews, including PMC-indexed orthopedic summaries, report pain improvement for selected tendinopathy or knee osteoarthritis protocols. Other trials are negative or show effects similar to placebo or hyaluronic acid. Leukocyte content, platelet dose, and image guidance vary so widely that “PRP works” is not a usable sentence.

PRF is common in dental surgery as a membrane or clot. That dental literature does not automatically justify musculoskeletal or aesthetic injections. BMAC harvests a mix of marrow cells; stromal progenitors are a small fraction. Predictable cartilage regrowth has not been established. Harvest adds donor-site pain and, rarely, more serious marrow-aspiration complications.

Donor amniotic, cord, and Wharton’s jelly products are often sold as stem-cell therapy. FDA consumer alerts on regenerative-medicine products, including stem cells and exosomes, warn that many offerings are unproven and that serious infections have occurred. Patient-information pages tell you to ask whether the product is approved or being studied under an IND, and not to treat “FDA registered” as approval.

NIAMS osteoarthritis materials still emphasize diagnosis, activity, weight management when relevant, topical or oral medicines, injections that have a longer evidence trail, and surgery for selected people. An orthobiologic that might help pain in some protocols is not a license to abandon that path. Structural “regrowth” advertisements oversell what mixed trials support.

Common myths

Myth: autologous means unregulated and harmless. Processing devices may be cleared to prepare blood. That clearance is not an arthritis-cure approval. Infection, bleeding, flare, and nerve or vascular injury still happen. If a clinic cultures, expands, or enzymatically digests cells, the regulatory category can change entirely.

Myth: BMAC or fat is a stem-cell transplant. These are heterogeneous mixtures. They are not the same as an FDA-approved cellular drug. Calling every pellet “stem cells” is the marketing move FDA’s consumer alert describes.

Myth: donor birth tissue is automatically younger and therefore better. Age of the donor tissue is not a validated superiority claim for your knee. You inherit donor-screening questions, lot identity, and a different FDA pathway. A cheaper vial with no lot number is a sterility and identity problem.

Myth: one product treats joints, nerves, lungs, and aging. That is a red flag on FDA’s regenerative-medicine patient page: the same offering for unrelated diseases. Biology is not a brand that scales to every organ.

How clinics use it

Sports-medicine and orthopedic clinics may offer PRP after they have an imaging diagnosis and a rehabilitation plan, often as a cash adjunct when conservative care is incomplete. Better practice names the target, uses ultrasound or fluoroscopy when placement matters, and schedules physical therapy. Worse practice injects “whatever we spun” into several sites in one visit and calls it a protocol.

Longevity and regenerative storefronts often blur autologous and donor products, hang “stem cell” on the wall, and sell packages for arthritis, back pain, and systemic disease. FDA tissue pages and consumer alerts exist because those claims have outrun approvals. Pay-to-participate “trials” without an IND, IRB, or monitoring are research theater.

Ask for the generic description, kit or manufacturer, autologous versus donor, lot and expiration for donor products, processing steps, final volume, and the exact regulatory story: device clearance, HCT/P homologous-use rationale, approval, or IND. Then ask what outcome would count as success in three months besides a testimonial.

Image guidance, sterile technique, and a plan for flare or infection belong in the same conversation. A centrifuge in a back room is not a quality system. If the clinic also sells exosomes or expanded cells for IV use, read FDA’s alert before you book the orthopedic visit—the culture of claims is the same.

Practical takeaway

Name the product before you name the hope. PRP, PRF, BMAC, and donor birth-tissue injections are different. Autologous versus donor changes infection questions and FDA rules. Neither category is a guaranteed cartilage repair.

Start with a licensed orthopedic, sports-medicine, or physical-medicine clinician and a diagnosis. Use NIAMS-style standard care first. If you still consider an orthobiologic, match published evidence to that exact product, route, and diagnosis. Mixed evidence is a reason to be picky, not a reason to prepay a series.

Refuse guaranteed regrowth, stem-cell language for PRP, and one vial for unrelated diseases. Refuse missing lot numbers on donor tissue and “registered equals approved.” Keep surgery referral on the table when NIAMS-style criteria may apply.

Orthobiologics can be a cautious adjunct in selected orthopedic care. They are not a fountain-of-youth class. FDA product rules still apply when the centrifuge is in a boutique and the story is regenerative.